Replies to post #1338 on Cassava Sciences Inc (SAVA)

[mcsharkey]

Dunno (don't know) about your peer review here Pineapple???¿. Maybe you could expand on the descriptions of the acronyms you cite as critical factors not aligning with this excerpt from 5th December piece

12th International Conference on Clinical Trials on Alzheimer’s Disease (CTAD), in San Diego, Ca. Link to full article

Consistent with over 10 years of basic research and pre-clinical data, the new data show clinical evidence of PTI-125’s mechanism of action and drug-target engagement, including:

Improvements in biomarkers of Alzheimer’s disease in plasma and lymphocytes;
Consistency across biomarker improvements in CSF, plasma, and lymphocytes;
Significant reductions (p<0.01) in both nitrated and phosphorylated forms of tau protein;
Evidence that each individual patient showed biomarker responses to PTI-125;
Evidence that PTI-125 reversed the shape of altered filamin A in lymphocytes;
Early clinical validation of the drug target – altered filamin A – as a facilitator protein between amyloid beta and both neuroinflammation and tau pathology.
Cassava Sciences expects to publish a manuscript of these new clinical data in a peer-reviewed medical journal.......

Appreciate any citations.